$40.87
-5.0%Aimei Health Technology Co., Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Negative working capital with limited cash reserves requires immediate attention—potential liquidity crisis if not addressed promptly.
AFJK • NASDAQ
| Aimei Health Technology Co., Ltd Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
ASSETS | |||
CURRENT ASSETS | |||
2.9K | 28.2K | 580.7K | |
2.9K | 28.2K | 580.7K | |
0.0 | 2.2K | 0.0 | |
2.9K | 30.4K | 580.7K | |
NON-CURRENT ASSETS | |||
12.1M | 73.8M | 0.0 | |
0.0 | 0.0 | 69.9M | |
12.1M | 73.8M | 69.9M | |
12.1M | 73.8M | 70.5M | |
LIABILITIES | |||
CURRENT LIABILITIES | |||
0.0 | 289.8K | 0.0 | |
0.0 | 289.8K | 0.0 | |
0.0 | 299.5K | 24.8K | |
2M | 227.7K | 0.0 | |
1.3M | 0.0 | 0.0 | |
3.4M | 817K | 24.8K | |
NON-CURRENT LIABILITIES | |||
690K | 690K | 690K | |
690K | 690K | 690K | |
4.1M | 1.5M | 714.8K | |
SHAREHOLDERS' EQUITY | |||
12.1M | 73.8M | 69.9M | |
-4.1M | -1.5M | -134.3K | |
8M | 72.3M | 69.8M | |
8M | 72.3M | 69.8M | |
SUMMARY | |||
12.1M | 73.8M | 70.5M | |
12.1M | 73.8M | 0.0 | |
2M | 227.7K | 0.0 | |
2M | 199.5K | -580.7K | |
6,121,733 | 6,121,733 | 6,121,733 |
AFJK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 20, 2026 | May 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
10-K 10-K 2025 FY FY | May 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 02, 2025 | November 26, 2025 | 2025 |
Continue your AFJK research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.